Concord Wealth Partners Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Concord Wealth Partners grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,262 shares of the biopharmaceutical company’s stock after buying an additional 273 shares during the quarter. Concord Wealth Partners’ holdings in Regeneron Pharmaceuticals were worth $899,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at $127,489,000. KBC Group NV raised its stake in Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after buying an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 18,342.0% during the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after buying an additional 75,569 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $672.98 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50-day simple moving average is $720.81 and its 200 day simple moving average is $924.07. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The firm has a market capitalization of $73.95 billion, a PE ratio of 16.65, a P/E/G ratio of 1.62 and a beta of 0.10.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada dropped their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. Finally, UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.